Eiko Sakagawa
- Molecular Medicine top 0.2%
- Molecular Biology
- Pharmacology top 2%
- Genetics top 10%
- Endocrinology top 2%
- Co-authors
- Satoshi OhyaNobuhisa MasudaNaomasa GotohTakeshi NishinoHideto TsujimotoT NishinoHajime TsujimotoMasako Otsuki
- Topics
- Antibiotic Resistance in Bacteria (8 papers)Antibiotics Pharmacokinetics and Efficacy (5 papers)Pneumonia and Respiratory Infections (2 papers)
- Journals
- Antimicrobial Agents and ChemotherapyJournal of Antimicrobial ChemotherapyKansenshogaku zasshi
- Partner nations
- JapanUnited States
In The Last Decade
Eiko Sakagawa
10 papers receiving 1.2k citations
Hit Papers
Peers
Comparison fields: 5 of 70
- Molecular Medicine 1.0k
- Molecular Biology 572
- Pharmacology 383
- Genetics 274
- Endocrinology 203
Countries citing papers authored by Eiko Sakagawa
This map shows the geographic impact of Eiko Sakagawa's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eiko Sakagawa with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eiko Sakagawa more than expected).
Fields of papers citing papers by Eiko Sakagawa
This network shows the impact of papers produced by Eiko Sakagawa. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eiko Sakagawa. The network helps show where Eiko Sakagawa may publish in the future.
Co-authorship network of co-authors of Eiko Sakagawa
This figure shows the co-authorship network connecting the top 25 collaborators of Eiko Sakagawa. A scholar is included among the top collaborators of Eiko Sakagawa based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eiko Sakagawa. Eiko Sakagawa is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 29 | |
| 2 | 227 | |
| 3 | SUBSTRATE SPECIFICITIES OF MEXABOPRM, MEXCD-OPRJ, AND MEXXYOPRM EFFLUX PUMPS IN PSEUDOMONAS AERUGINOSA | 83 |
| 4 | Substrate Specificities of MexAB-OprM, MexCD-OprJ, and MexXY-OprM Efflux Pumps in Pseudomonas aeruginosabreakdown → | 559 |
| 5 | 38 | |
| 6 | 84 | |
| 7 | 2 | |
| 8 | 14 | |
| 9 | 22 | |
| 10 | 192 |
About Eiko Sakagawa
Eiko Sakagawa is a scholar working on Molecular Medicine, Pharmacology and Endocrinology, having authored 10 papers that have together received 1.3k indexed citations. Recurring topics across this work include Antibiotic Resistance in Bacteria (8 papers), Antibiotics Pharmacokinetics and Efficacy (5 papers) and Pneumonia and Respiratory Infections (2 papers). The work is most often cited by research in Molecular Medicine (1.0k citations), Applied Microbiology and Biotechnology (89 citations) and Endocrinology (203 citations). Eiko Sakagawa has collaborated with scholars based in Japan and United States. Frequent co-authors include Satoshi Ohya, Nobuhisa Masuda, Naomasa Gotoh, Takeshi Nishino, Hideto Tsujimoto, T Nishino, Hajime Tsujimoto, Masako Otsuki, Masayo Kakuta and Hisataka Yasuda. Their work appears in journals such as Antimicrobial Agents and Chemotherapy, Journal of Antimicrobial Chemotherapy and Kansenshogaku zasshi.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.